8-K Announcements
6Material company update
Apr 16, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Apr 7, 2026·SEC
Corbus Pharmaceuticals Holdings, Inc.(CRBP)Earnings, Financials & Key Ratios
CRBP•NASDAQ
$10.99
$138M mkt cap·Price updated May 6, 2026
AboutCorbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Show more
- Revenue$0
- EBITDA-$85M-76.8%
- Net Income-$79M-95.3%
- EPS (Diluted)-5.90-60.3%
- ROE-54.18%+8.7%
- ROIC-51.37%+9.5%
- Debt/Equity0.01-51.3%
CRBP Key Insights
Corbus Pharmaceuticals Holdings, Inc. (CRBP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 22.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CRBP Price & Volume
Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock price & volume — 10-year historical chart
Loading chart...
CRBP Growth Metrics
Corbus Pharmaceuticals Holdings, Inc. (CRBP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-95.32%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM24.59%
Return on Capital
10 Years-151.8%
5 Years-85.16%
3 Years-102.68%
Last Year-58.52%
CRBP Recent Earnings
Corbus Pharmaceuticals Holdings, Inc. (CRBP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
Mar 9, 2026EPS
$1.25
Est $1.78
+29.8%
Revenue
—
Est $2M
Q4 2025
Nov 12, 2025EPS
$1.90
Est $1.80
-5.6%
Revenue
—
Est $1M
Q3 2025
Aug 5, 2025EPS
$1.44
Est $1.55
+7.1%
Revenue
—
Q2 2025
May 6, 2025EPS
$1.39
Est $1.26
-10.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 9, 2026 | $1.25vs $1.78+29.8% | —vs $2M |
| Q4 2025 | Nov 12, 2025 | $1.90vs $1.80-5.6% | —vs $1M |
| Q3 2025 | Aug 5, 2025 | $1.44vs $1.55+7.1% | — |
| Q2 2025 | May 6, 2025 | $1.39vs $1.26-10.3% | — |
Based on last 12 quarters of dataView full earnings history →
CRBP Peer Comparison
Corbus Pharmaceuticals Holdings, Inc. (CRBP) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AGIO | 1.6B | 26.98 | -3.79 | 48.03% | -6.4% | -34.11% | 0.05 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% | ||
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 INCY | 19.95B | 99.85 | 15.58 | 21.22% | 26.71% | 29.31% | 0.01 |
Compare CRBP vs Peers
Corbus Pharmaceuticals Holdings, Inc. (CRBP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CRBP Income Statement
Corbus Pharmaceuticals Holdings, Inc. (CRBP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.44M | 4.82M | 36.14M | 3.94M | 881.71K | 0 | 0 | 0 | 0 |
| Revenue Growth % | 27.66% | 97.62% | 649.51% | -89.11% | -77.61% | -100% | - | - | - |
| Cost of Goods Sold | 26.04M | 48.61M | 89.6M | 0 | 1.64M | 1.49M | 0 | 600K | 233K |
| COGS % of Revenue | 1067.09% | 1008.11% | 247.91% | - | 185.92% | - | - | - | - |
| Gross Profit | -23.6M▲ 0% | -43.79M▼ 85.6% | -53.46M▼ 22.1% | 3.94M▲ 107.4% | -757.53K▼ 119.2% | -1.49M▼ 96.4% | 0▲ 100.0% | -600K▲ 0% | -233K▲ 61.2% |
| Gross Margin % | -967.09% | -908.11% | -147.91% | 100% | -85.92% | - | - | - | - |
| Gross Profit Growth % | -74.48% | -85.57% | -22.08% | 107.36% | -119.24% | -96.41% | 100% | - | 61.17% |
| Operating Expenses | 35M | 61.57M | 23.64M | 126.75M | 55.23M | 33.35M | 45.08M | 48.12M | 85.31M |
| OpEx % of Revenue | 1434.43% | 1276.78% | 65.42% | 3219.2% | 6264.17% | - | - | - | - |
| Selling, General & Admin | 8.96M | 12.96M | 23.64M | 28.48M | 20.43M | 18.7M | 13.91M | 16.5M | 15.21M |
| SG&A % of Revenue | 367.35% | 268.67% | 65.42% | 723.36% | 2316.58% | - | - | - | - |
| Research & Development | 26.04M | 48.61M | 89.6M | 98.27M | 36.45M | 16.14M | 31.17M | 32.22M | 70.09M |
| R&D % of Revenue | 1067.09% | 1008.11% | 247.91% | 2495.85% | 4133.5% | - | - | - | - |
| Other Operating Expenses | 0 | 0 | -89.6M | 0 | -1.64M | -1.49M | 0 | -600K | 0 |
| Operating Income | -32.56M▲ 0% | -56.75M▼ 74.3% | -77.1M▼ 35.9% | -122.81M▼ 59.3% | -55.99M▲ 54.4% | -34.84M▲ 37.8% | -45.08M▼ 29.4% | -48.72M▼ 8.1% | -85.31M▼ 75.1% |
| Operating Margin % | -1334.43% | -1176.78% | -213.33% | -3119.2% | -6350.09% | - | - | - | - |
| Operating Income Growth % | -62.94% | -74.27% | -35.87% | -59.28% | 54.41% | 37.78% | -29.4% | -8.08% | -75.1% |
| EBITDA | -32.31M | -56.25M | -76.37M | -121.12M | -54.35M | -33.35M | -44.44M | -48.12M | -85.08M |
| EBITDA Margin % | -1323.96% | -1166.54% | -211.28% | -3076.17% | -6164.17% | - | - | - | - |
| EBITDA Growth % | -62.37% | -74.12% | -35.75% | -58.6% | 55.13% | 38.64% | -33.25% | -8.29% | -76.8% |
| D&A (Non-Cash Add-back) | 255.65K | 493.94K | 739.38K | 1.69M | 1.64M | 1.49M | 641K | 600K | 233K |
| EBIT | -32.56M | -56.75M | -77.1M | -122.81M | -55.99M | -40.21M | -40.75M | -38.34M | -85.31M |
| Net Interest Income | 183.11K | 982.78K | 1.23M | -1.03M | -1.83M | -2.13M | -2.92M | 4.44M | 5.53M |
| Interest Income | 183.11K | 982.78K | 1.23M | 0 | 0 | 0 | 0 | 6.31M | 5.53M |
| Interest Expense | 0 | 0 | 0 | 1.03M | 1.83M | 2.13M | 2.92M | 1.87M | 0 |
| Other Income/Expense | 141.2K | 1.08M | 5.65M | 11.54M | 10.35M | -7.51M | 474K | 8.51M | 6.77M |
| Pretax Income | -32.42M▲ 0% | -55.67M▼ 71.7% | -71.45M▼ 28.3% | -111.27M▼ 55.7% | -45.64M▲ 59.0% | -42.35M▲ 7.2% | -44.6M▼ 5.3% | -40.21M▲ 9.9% | -78.54M▼ 95.3% |
| Pretax Margin % | -1328.65% | -1154.48% | -197.69% | -2826.08% | -5176.38% | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -32.42M▲ 0% | -55.67M▼ 71.7% | -71.45M▼ 28.3% | -111.27M▼ 55.7% | -45.55M▲ 59.1% | -55.83M▼ 22.6% | -44.6M▲ 20.1% | -40.21M▲ 9.9% | -78.54M▼ 95.3% |
| Net Margin % | -1328.65% | -1154.48% | -197.69% | -2826.08% | -5166.42% | - | - | - | - |
| Net Income Growth % | -62.12% | -71.71% | -28.35% | -55.72% | 59.06% | -22.57% | 20.11% | 9.85% | -95.32% |
| Net Income (Continuing) | -32.42M | -55.67M | -71.45M | -111.27M | -45.64M | -42.35M | -44.6M | -40.21M | -78.54M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -19.38▲ 0% | -29.30▼ 51.2% | -32.47▼ 10.8% | -42.74▼ 31.6% | -11.11▲ 74.0% | -10.15▲ 8.6% | -10.31▼ 1.6% | -3.68▲ 64.3% | -5.90▼ 60.3% |
| EPS Growth % | -32.92% | -51.19% | -10.82% | -31.63% | 74.01% | 8.64% | -1.58% | 64.31% | -60.33% |
| EPS (Basic) | -19.38 | -29.30 | -32.47 | -42.74 | -11.11 | -10.15 | -10.31 | -3.68 | -5.90 |
| Diluted Shares Outstanding | 1.67M | 1.9M | 2.13M | 2.6M | 4.1M | 4.17M | 4.33M | 10.91M | 13.32M |
| Basic Shares Outstanding | 1.67M | 1.9M | 2.13M | 2.6M | 4.1M | 4.17M | 4.33M | 10.91M | 13.32M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CRBP Balance Sheet
Corbus Pharmaceuticals Holdings, Inc. (CRBP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 65.5M | 44.24M | 38.15M | 92.07M | 100.2M | 60.18M | 23.55M | 152.98M | 166.95M |
| Cash & Short-Term Investments | 62.54M | 41.75M | 31.75M | 85.43M | 97.65M | 59.2M | 20.91M | 149.06M | 163.94M |
| Cash Only | 62.54M | 41.75M | 31.75M | 85.43M | 25.01M | 17M | 13.72M | 17.2M | 28.49M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 72.64M | 42.19M | 7.18M | 131.86M | 134.78M |
| Accounts Receivable | 0 | 0 | 2.68M | 2.58M | 0 | 0 | 0 | 0 | 1.5M |
| Days Sales Outstanding | - | - | 27.07 | 239.02 | - | - | - | - | - |
| Inventory | 0 | 0 | -2.68M | 350K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 158.99K | 2.49M | 2.68M | 0 | 192.47K | 192.47K | 192K | 3.91M | 1.51M |
| Total Non-Current Assets | 1.47M | 2.75M | 10.99M | 10.22M | 7.53M | 6.13M | 4.73M | 2.9M | 1.24M |
| Property, Plant & Equipment | 1.43M | 2.71M | 10.9M | 9.32M | 7M | 5.5M | 4.04M | 2.52M | 1.24M |
| Fixed Asset Turnover | 1.70x | 1.78x | 3.32x | 0.42x | 0.13x | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 669.9K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 40.78K | 43.82K | 84.97K | 234.04K | 523.81K | 632.77K | 690K | 385K | 0 |
| Total Assets | 66.98M▲ 0% | 46.99M▼ 29.8% | 49.14M▲ 4.6% | 102.29M▲ 108.2% | 107.73M▲ 5.3% | 66.31M▼ 38.4% | 28.27M▼ 57.4% | 155.88M▲ 451.4% | 168.19M▲ 7.9% |
| Asset Turnover | 0.04x | 0.10x | 0.74x | 0.04x | 0.01x | - | - | - | - |
| Asset Growth % | 274.43% | -29.84% | 4.58% | 108.16% | 5.31% | -38.45% | -57.37% | 451.35% | 7.9% |
| Total Current Liabilities | 8.2M | 18.09M | 34.89M | 31.9M | 17.01M | 12.64M | 31.89M | 11.82M | 20.69M |
| Accounts Payable | 3.13M | 6.35M | 11.09M | 7.38M | 1.78M | 2.17M | 3.18M | 4.79M | 2.21M |
| Days Payables Outstanding | 43.88 | 47.64 | 45.18 | - | 396.85 | 533.32 | - | 2.91K | 3.47K |
| Short-Term Debt | 332.86K | 394.31K | 752.66K | 710.16K | 3.86M | 3.15M | 16.21M | 0 | 0 |
| Deferred Revenue (Current) | 0 | 1.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 7.63M | 3.67M | 797K | 133.71K | 36.87K | 39K | 2.28M | 16.84M |
| Current Ratio | 7.98x | 2.45x | 1.09x | 2.89x | 5.89x | 4.76x | 0.74x | 12.94x | 8.07x |
| Quick Ratio | 7.98x | 2.45x | 1.17x | 2.88x | 5.89x | 4.76x | 0.74x | 12.94x | 8.07x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 989.92K | 1.38M | 8.1M | 25.12M | 21.61M | 20.68M | 3.28M | 1.63M | 0 |
| Long-Term Debt | 0 | 0 | 0 | 18.03M | 15.64M | 15.98M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 8.1M | 7.09M | 5.96M | 4.68M | 3.24M | 1.63M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 989.92K | 1.38M | 0 | 0 | 22.2K | 22.2K | 44K | 0 | 0 |
| Total Liabilities | 9.19M | 19.47M | 42.98M | 57.02M | 38.62M | 33.32M | 35.18M | 13.45M | 20.69M |
| Total Debt | 332.86K | 394.31K | 9.45M | 26.84M | 26.59M | 25.09M | 20.89M | 3.24M | 1.63M |
| Net Debt | -62.2M | -41.35M | -22.3M | -58.6M | 1.58M | 8.09M | 7.16M | -13.96M | -26.86M |
| Debt / Equity | 0.01x | 0.01x | 1.53x | 0.59x | 0.38x | 0.76x | - | 0.02x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | -119.42x | -30.59x | -18.86x | -13.94x | -20.48x | - |
| Total Equity | 57.78M▲ 0% | 27.52M▼ 52.4% | 6.16M▼ 77.6% | 45.27M▲ 635.3% | 69.11M▲ 52.6% | 32.99M▼ 52.3% | -6.91M▼ 120.9% | 142.43M▲ 2162.7% | 147.5M▲ 3.6% |
| Equity Growth % | 547.85% | -52.37% | -77.63% | 635.27% | 52.64% | -52.26% | -120.93% | 2162.68% | 3.56% |
| Book Value per Share | 34.55 | 14.49 | 2.89 | 17.38 | 16.86 | 7.91 | -1.60 | 13.05 | 11.08 |
| Total Shareholders' Equity | 57.78M | 27.52M | 6.16M | 45.27M | 69.11M | 32.99M | -6.91M | 142.43M | 147.5M |
| Common Stock | 5.56K | 5.72K | 6.47K | 9.88K | 12.52K | 417 | 0 | 1K | 2K |
| Retained Earnings | -65.7M | -121.37M | -192.82M | -304.09M | -349.73M | -392.08M | -436.68M | -476.89M | -555.43M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -363.89K | -666.58K | 0 | 0 | -62.45K | -126.09K | -1K | 35K | -53K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRBP Cash Flow Statement
Corbus Pharmaceuticals Holdings, Inc. (CRBP) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -27.8M | -30.07M | -45.72M | -99.69M | -48.18M | -37.54M | -36.1M | -41.79M | -64.49M |
| Operating CF Margin % | -1139.12% | -623.51% | -126.5% | -2531.87% | -5464.83% | - | - | - | - |
| Operating CF Growth % | -104.82% | -8.17% | -52.06% | -118.03% | 51.66% | 22.08% | 3.85% | -15.77% | -54.31% |
| Net Income | -32.42M | -55.67M | -71.45M | -111.27M | -45.64M | -42.35M | -44.6M | -40.21M | -78.54M |
| Depreciation & Amortization | 255.65K | 493.94K | 1.23M | 1.69M | 1.64M | 1.49M | 641K | -2.74M | -1.13M |
| Stock-Based Compensation | 5.69M | 7.61M | 11.98M | 12.46M | 9.48M | 5.72M | 0 | 6.14M | 6.29M |
| Deferred Taxes | -8.49K | 70.45K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 913.56K | 422.34K | 45.83K | 636.05K | 2.03M | 1.62M | 3.77M | 585K | -229K |
| Working Capital Changes | -2.23M | 17.01M | 12.48M | -3.2M | -15.7M | -4.02M | 4.09M | -5.58M | 9.12M |
| Change in Receivables | 1M | 12.5M | 2.32M | 1.06M | 1.62M | 0 | 0 | 0 | 0 |
| Change in Inventory | -404.24K | 5.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -885.8K | 3.9M | 4.37M | -3.47M | -5.96M | -256.83K | 1.03M | 1.6M | -2.35M |
| Cash from Investing | -707.43K | -2.3M | -2.74M | -484.49K | -73.42M | 30.07M | 35.64M | -121.31M | -1.64M |
| Capital Expenditures | -707.43K | -2.3M | -2.74M | -484.49K | -54.17K | -13.45K | 0 | 0 | -7K |
| CapEx % of Revenue | 28.99% | 47.7% | 7.59% | 12.31% | 6.14% | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 8.1K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 23.9K | 0 | 0 | 0 | 0 |
| Cash from Financing | 76.01M | 11.42M | 38.46M | 154.87M | 60.82M | -533.62K | -2.82M | 166.58M | 77.43M |
| Debt Issued (Net) | 57.27K | 57.19K | 357.98K | 18.71M | 57.78K | -533.62K | -2.87M | -15.48M | 0 |
| Equity Issued (Net) | 78.89M | 12.05M | 40.68M | 136.16M | 62.59M | 0 | 53.4K | 182.06M | 77.43M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -2.94M | -690.18K | -2.57M | 0 | -1.82M | 0 | 0 | 0 | 0 |
| Net Change in Cash | 47.5M▲ 0% | -20.95M▼ 144.1% | -10M▲ 52.3% | 54.03M▲ 640.4% | -60.78M▼ 212.5% | -8M▲ 86.8% | -3.28M▲ 59.0% | 3.47M▲ 205.9% | 11.29M▲ 225.1% |
| Free Cash Flow | -28.5M▲ 0% | -32.37M▼ 13.6% | -48.46M▼ 49.7% | -100.17M▼ 106.7% | -48.24M▲ 51.8% | -37.56M▲ 22.1% | -36.1M▲ 3.9% | -41.79M▼ 15.8% | -64.5M▼ 54.3% |
| FCF Margin % | -1168.11% | -671.21% | -134.09% | -2544.18% | -5470.98% | - | - | - | - |
| FCF Growth % | -104.71% | -13.55% | -49.73% | -106.69% | 51.84% | 22.14% | 3.88% | -15.77% | -54.32% |
| FCF per Share | -17.04 | -17.04 | -22.75 | -38.46 | -11.77 | -9.01 | -8.34 | -3.83 | -4.84 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.54x | 0.64x | 0.90x | 1.06x | 0.67x | 0.81x | 1.04x | 0.82x |
| Interest Paid | 0 | 0 | 29.45K | 0 | 1.74M | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CRBP Key Ratios
Corbus Pharmaceuticals Holdings, Inc. (CRBP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -223.4% | -97.21% | -130.52% | -424.29% | -432.68% | -79.65% | -109.37% | -341.99% | -59.34% | -54.18% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -146.39% | -46.75% | -163.59% | -56.77% | -51.37% |
| Gross Margin | -707.6% | -967.09% | -908.11% | -147.91% | 100% | -85.92% | - | - | - | - |
| Net Margin | -1046.27% | -1328.65% | -1154.48% | -197.69% | -2826.08% | -5166.42% | - | - | - | - |
| Debt / Equity | 0.03x | 0.01x | 0.01x | 1.53x | 0.59x | 0.38x | 0.76x | - | 0.02x | 0.01x |
| Interest Coverage | - | - | - | - | -119.42x | -30.59x | -18.86x | -13.94x | -20.48x | - |
| FCF Conversion | 0.68x | 0.86x | 0.54x | 0.64x | 0.90x | 1.06x | 0.67x | 0.81x | 1.04x | 0.82x |
| Revenue Growth | 194.8% | 27.66% | 97.62% | 649.51% | -89.11% | -77.61% | -100% | - | - | - |
CRBP SEC Filings & Documents
Corbus Pharmaceuticals Holdings, Inc. (CRBP) SEC filings — annual & quarterly reports (10-K, 10-Q)
CRBP Frequently Asked Questions
Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Corbus Pharmaceuticals Holdings, Inc. (CRBP) grew revenue by 0.0% over the past year. Growth has been modest.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported a net loss of $78.5M for fiscal year 2025.
Dividend & Returns
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a return on equity (ROE) of -54.2%. Negative ROE indicates the company is unprofitable.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had negative free cash flow of $64.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More CRBP
Corbus Pharmaceuticals Holdings, Inc. (CRBP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates